Several potentially targetable mutations were also identified, including mutations in KRAS and RET. KRAS mutations were detected in one LCC patient (p.G12V) and one LCNEC patient (p.G12C). The gene discussed is RET; the disease is large cell neuroendocrine carcinoma.